FDA Launches Framework to Accelerate Individualized Therapies for Ultra-Rare Diseases 2026
oncodaily - The U.S. Food and Drug Administration (FDA) has released groundbreaking draft guidance introducing a new regulatory framework designed to accelerate the development and approval of individualized therapies for patients with […]
AI Summary: The FDA released draft guidance creating a regulatory pathway to speed individualized and N-of-1 cell and gene therapies for ultra‑rare diseases. The framework clarifies evidence expectations, manufacturing and safety-monitoring options, and trial design flexibility to help get bespoke treatments from bench to bedside faster — no miracles promised, just fewer bureaucratic speed bumps.
Related Stories
FDA links eight deaths to Amgen’s Tavneos; scrutiny intensifies / 3 months
FDA makes one pivotal trial the default for drug approvals / 4 months
FDA refuses to review Moderna mRNA flu vaccine application / 5 months
FDA rejects Atara cell therapy for Epstein–Barr virus complications / 5 months
Boehringer gains fast approval for first‑line lung cancer drug via voucher program / 4 months
FDA clears first new sunscreen ingredient in two decades / 28 days
FDA commissioner Marty Makary resigns amid mounting scrutiny / 1 month
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Weight Loss, CDC, Supplements, Health Disparities and look for the RSS link.
StackHealth Time Machine